The University of Maine

DigitalCommons@UMaine
Miscellaneous Reports

Maine Agricultural and Forest Experiment Station

12-2003

MR432: The Business Climate for Biotechnology
in Maine
Thomas G. Allen
Todd M. Gabe

Follow this and additional works at: https://digitalcommons.library.umaine.edu/aes_miscreports
Part of the Agricultural and Resource Economics Commons
Recommended Citation
Allen, T.G., and T.M. Gabe. 2003. The business climate for biotechnology in Maine. Maine Agricultural and Forest Experiment Station
Miscellaneous Report 432.

This Report is brought to you for free and open access by DigitalCommons@UMaine. It has been accepted for inclusion in Miscellaneous Reports by
an authorized administrator of DigitalCommons@UMaine. For more information, please contact um.library.technical.services@maine.edu.

ISSN 1070-1516

The Business Climate for Biotechnology in Maine
Thomas G. Allen
and
Todd M. Gabe

Miscellaneous Report 432
MAINE AGRICULTURAL AND FOREST EXPERIMENT STATION
University of Maine

December 2003

The Business Climate for Biotechnology in Maine

Thomas G. Allen
Associate Scientist
and
Todd M. Gabe
Assistant Professor

Department of Resource Economics and Policy
5782 Winslow Hall
The University of Maine
Orono ME 04469-5782

ACKNOWLEDGEMENTS
The Maine Technology Institute, the Biotechnology Association of Maine, the Maine Center for
Innovation in Biotechnology, and the Maine Agricultural and Forest Experiment Station provided financial
support for this study.

The Maine Agricultural and Forest Experiment Station provides equal program opportunities without
regard to race, age, sex or preference, creed, national origin, or disability.
In complying with the letter and spirit of applicable laws and in pursuing its own goals of diversity, the
University of Maine System shall not discriminate on the grounds of race, color, religion, sex, sexual
orientation, national origin or citizenship status, age, disability, or veterans’ status in employment, education,
and all other areas of the University. The University provides reasonable accommodations to qualified
individuals with disabilities upon request.
Questions and complaints about discrimination in any area of the University should be directed to the
Director of Equal Opportunity, 101 North Stevens, (207) 581-1226.

Contents
EXECUTIVE SUMMARY .................................................................................................................................................... 1
Recommendations ............................................................................................................................................................. 1
INTRODUCTION ................................................................................................................................................................. 2
INDUSTRY BACKGROUND ............................................................................................................................................ 2
SURVEY DATA COLLECTION ....................................................................................................................................... 2
COMPANY DEMOGRAPHIC CHARACTERISTICS ................................................................................................. 3
BIOTECHNOLOGY INVESTMENT AND INNOVATION .................................................................................. 5
COOPERATIVE ACTIVITY ............................................................................................................................................... 6
ASSISTANCE RECEIVED BY MAINE BIOTECHNOLOGY FIRMS ................................................................. 8
BUSINESS CLIMATE ........................................................................................................................................................... 9
Financing Issues ................................................................................................................................................................ 10
Business Costs and Regulations ..................................................................................................................................... 10
Local Issues ....................................................................................................................................................................... 12
Other Business-Climate Factors .................................................................................................................................... 12
RESPONSES TO OPEN-ENDED QUESTIONS ..................................................................................................... 12
SUMMARY AND CONCLUSIONS ............................................................................................................................... 13
LITERATURE CITED ........................................................................................................................................................ 14
APPENDIX: SURVEY INSTRUMENT ........................................................................................................................ 15

Tables
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.

Biotechnology activity in Maine, 2002. ........................................................................................................................... 3
Industry categories of Maine biotechnology firms. ..................................................................................................... 4
Investments in Maine biotechnology companies, 2002. .............................................................................................. 5
Sources of R&D funding, 2002. ..................................................................................................................................... 6
Key sources of R&D funding, by firm size. ................................................................................................................ 6
Partnerships of Maine biotechnology firms. ................................................................................................................ 7
Important sources of biotechnology workers. ............................................................................................................ 8
State government programs for biotechnology. .......................................................................................................... 9
Entities that support Maine biotechnology firms. ........................................................................................................ 9
Average ratings of business-climate factors. ................................................................................................................ 11

Figures
1. Locations of Maine biotechnology companies. ........................................................................................................... 4
2. Planned strategies of Maine biotechnology firms. ....................................................................................................... 8
3. Maine’s business climate for biotechnology. ................................................................................................................ 10

Maine Agricultural and Forest Experiment Station Miscellaneous Report 432

EXECUTIVE SUMMARY
The biotechnology industry in Maine consists of
approximately 80 businesses. These companies are
engaged in research and development and the manufacturing and provision of a wide variety of products
and services. The businesses cover a broad spectrum of the biotechnology industry, from human
diagnostics to marine biotechnology to genomics
and proteomics. Biotechnology firms are highly concentrated in southern Maine, but they also operate
in ten of the state’s sixteen counties. A study of the
industry conducted in 2002 found that these firms
generated a combined $432 million in annual sales
and employed 3,690 workers. Including multiplier
effects, the biotechnology industry contributed $685
million in output to the Maine economy in 2002 and
supported 7,135 Maine jobs.
This report presents the findings from a survey
of biotechnology firms located in Maine. The purpose of the survey, conducted during the spring of
2003, was to collect information on a variety of
issues related to the companies’ operations and the
state’s business climate for biotechnology. Some of
the issues addressed in the survey include the
research and development activities of Maine biotechnology companies, partnerships formed within
the biotechnology industry, and the companies’ participation in government-sponsored business assistance programs. The survey results present a “snap
shot” of the industry in 2002, which can be used to
establish a baseline against which to gauge future
growth and changes to the industry in Maine.
The survey results suggest that Maine biotechnology companies are actively involved in research
and development. Large companies generally finance the majority of their research and development expenditures through their own revenue
sources, while small businesses are likely to receive
support for research and development from statesponsored programs such as those administered by
the Maine Technology Institute. These research
and development activities appear to result in new
innovations, as 78% of the businesses plan to release a new product within the next three years.
Further, Maine biotechnology companies hold an
average of 2.3 patents and 0.7 patents pending.
Opportunities for interaction among Maine biotechnology businesses and other organizations in
Maine seem to be restricted by the diversity of
businesses within the industry, and the limited
awareness of the science and technology resources
available across the state. In almost every respect,
the biotechnology businesses in Maine are more
likely to engage in cooperative activities with part-
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ners from outside of the state than from within.
Thirty-five percent of Maine biotechnology businesses plan to form a joint venture in the near future
with an out-of-state partner, compared to 22% that
plan to do so with another Maine firm. By a ratio of
nearly five to one, businesses plan to obtain technology from a university outside of Maine rather than
from an in-state institution.
Biotechnology companies generally believe that
many of the costs of doing business in the state are
harmful to their growth. The majority of firms
report that the costs health care are, workers compensation, utilities, and state and local taxes are
relevant to the growth of their business. Further,
statistical analysis of the survey results suggests
that these cost factors have a significant negative
effect on a biotechnology company’s ability to grow
in Maine. On the other hand, the businesses indicated that the quality of life in Maine has a significant positive effect on their ability to grow. The rest
of the business climate factors included in the survey do not appear to have a significant effect, one
way or another, on the growth of Maine biotechnology businesses.

Recommendations
The State of Maine should offer general business assistance programs that will benefit a
broad range of biotechnology and other technology-intensive businesses.
• Steps should be taken to better promote the
programs and resources that are available
to biotechnology businesses in Maine to
create greater awareness of their availability.
• The public and private universities in Maine
should undertake a coordinated effort to
publicize the biotechnology-related research
and development activities and collaborations taking place at their respective institutions.
• The state should continue to support investments in basic research and development,
including assistance to smaller firms that
present promising development opportunities but that have few alternative sources of
investment capital
• Further analysis should be conducted on
the costs of doing business in Maine (taxes,
health care, utilities), which biotechnology
businesses report as having a negative effect on the growth of their operations.

2
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INTRODUCTION
This report presents the findings from a survey
of biotechnology firms located in Maine. The survey,
conducted during the spring of 2003, collected information on a variety of issues related to the companies’ operations and the state’s business climate for
biotechnology. Industry leaders and regional
policymakers may use the survey findings to develop policy recommendations and programs to help
strengthen the industry. The survey and this report
are part of a broader project funded by the Biotechnology Association of Maine, the Maine Center for
Innovation in Biotechnology, and the Maine Technology Institute. Other components of the project
include a report on the economic contribution of the
biotechnology industry to the Maine economy and
the creation of an interactive electronic network
available to biotechnology businesses and other
interested parties.
Economic activity in the United States is increasingly driven by technological innovation and
the development of knowledge-based resources. It is
important, therefore, that economic development
policies and programs at all levels of government
address the needs of technology-intensive industries. The characteristics of the state and local
business climate that encourage the development of
technology-intensive businesses are often thought
to be different from the locational attributes that
support the growth of traditional, nontechnologyintensive businesses. Some of the key factors believed to affect the growth of high-technology firms
are the presence of a skilled workforce, the availability of investment capital, access to university
and other research facilities, and opportunities for
business-to-business interaction. These issues are
addressed in this report.

INDUSTRY BACKGROUND
Biotechnology is increasingly important in
today’s modern economy. According to a recent
industry study, biotechnology-related firms in the
United States, not including the large multinational pharmaceutical companies, employed 150,000
workers and generated $20 billion in sales in 1999
(Ernst & Young 2000). Further, industry output
more than doubled between 1993 and 1999. The
impressive growth of the biotechnology industry
nationally has enticed many states, including Maine,
to pursue biotechnology development as a catalyst
for new business activity and investment. Maine’s
Science and Technology Action Plan 2001 (Maine

Science and Technology Foundation 2001) and the
State of Maine 2002 Economic Development Strategy (Maine Department of Economic and Community Development) both include biotechnology as a
sector targeted for development assistance.
A study of the Maine biotechnology industry
conducted in 2002 uncovered approximately 80
Maine businesses that were conducting research
and development in biotechnology, using biotechnology-related processes and products in manufacturing and provision of services, and producing
specialized products and services used in biotechnology. These firms generated a combined $432
million in annual sales and employed 3,690 workers. Including multiplier effects, the biotechnology
industry contributed $685 million in output to the
Maine economy in 2002 and supported 7,135 Maine
jobs (Allen and Gabe 2002).

SURVEY DATA COLLECTION
Unlike many industries (e.g., automotive, pulp
and paper) that are defined based on an easily
identifiable final product, the biotechnology sector
is defined more on the basis of a company’s process
of using living organisms to develop new products or
modify existing ones. For the purposes of this study,
biotechnology is defined as “any technique that uses
living organisms or parts of organisms to make or
modify products, to improve plants or animals, or to
develop microorganisms for specific uses” (Busch et
al. 1991). The survey population in our study covers
businesses and organizations in Maine that conduct
biotechnology-related research and development,
produce or use biotechnology products and services,
and manufacture specialized equipment and supplies used by biotechnology firms. The terms biotechnology “businesses,” “companies,” and “firms”
are used interchangeably throughout this report to
include businesses, in addition to research laboratories and institutions.
An anonymous survey of biotechnology companies operating in Maine was conducted during the
spring of 2003. This survey is contained in appendix
A at the end of the report. The questionnaire was
developed with input and advice from the Biotechnology Association of Maine and the survey instrument was pretested by a Maine biotechnology company. A mailing list of 80 companies was generated
from several electronic and print data sources, including general business directories, biotechnology
industry directories, and membership lists from the
Biotechnology Association of Maine. The Biotechnology Association of Maine used the mailing list to
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inform businesses of the forthcoming survey and to
solicit their participation.
After the Association received eight returned
mailings due to invalid addresses, an initial mailing
of 72 surveys was sent to Maine biotechnology
companies. A reminder postcard and replacement
survey was sent to nonrespondents, followed by a
telephone solicitation to selected businesses that
did not respond to the mailings. Two of the businesses that received surveys responded to indicate
that they were not involved in biotechnology-related activities. We received 40 completed surveys
from the revised sample of 70 firms, which translates into a response rate of 57%.
Based upon secondary data sources that list
employment figures for nearly all of the biotechnology firms in Maine, an analysis of the returned
surveys found that the firms that responded to the
survey were, on average, larger than those that did
not. To account for differences between the sample
of businesses that returned surveys and the overall
industry, the responses were grouped into five employment size categories and weighted accordingly.
The findings presented in this report are based on
the weighted survey results.

COMPANY DEMOGRAPHIC
CHARACTERISTICS
The biotechnology firms in Maine have been in
operation an average of 14.4 years and have been
located at their present site an average of 9.2 years.
One-fourth of the businesses are less than six years
old, and one-half of the firms are less than ten years
old. Twenty-eight percent of the firms have been in
business for more than 20 years. The survey results
indicate that 80% of the biotechnology businesses in
Maine are privately owned corporations, 10% are
public corporations, and the rest include
proprietorships and nonprofit organizations. Eightyone percent of the businesses are single establishment firms, 11% are the headquarters of a multiestablishment firm, and 8% are a branch plant of a
multi-establishment firm.
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Maine’s biotechnology industry is quite diverse,
both in terms of business size and the scope of
products and services developed and manufactured.
Table 1 shows that industry output and employment are highly concentrated in a few large firms,
with a relatively small amount of industry activity
contributed by smaller companies. The ten largest
biotechnology employers accounted for an estimated
81% of industry output and 85% of industry employment in 2002 (Allen and Gabe 2002).
The survey asked each company to indicate its
primary activity from the options of (1) research and
development, (2) making a product, or (3) providing
a service. Since many of the companies are involved
in multiple activities, such as manufacturing firms
that conduct research and development, the percentages of firms, by category, sum to more than
100%. Sixty-one percent of the biotechnology companies in Maine manufacture biotechnology-related
products, such as monoclonal antibodies or diagnostic test kits. Forty-six percent of the businesses
listed research and development as one of the
company’s primary activities. Finally, 34% of the
businesses are involved in the provision of biotechnology services, such as consulting, design and
contract laboratory work.
Companies were also asked to select, from the
options listed in Table 2, the category that best
describes their biotechnology operations. Once again,
the entries in the table sum to more than 100%
because many companies selected multiple categories. As shown in the far right-hand-side column of
Table 2, Maine’s biotechnology businesses are somewhat evenly distributed across the major fields of
biotechnology. The largest proportions of firms operate in the areas of human diagnostics (38%),
environmental biotechnology (36%), and marine
biotechnology (31%). The fewest numbers of firms
are engaged in human therapeutics (16%), industrial biotechnology (21%), and genomics or
proteomics (22%).
Figure 1 shows that the industry is highly geographically concentrated in southern Maine. Approximately 50% of biotechnology establishments
and 59% of biotechnology jobs are located in

Table 1. Biotechnology activity in Maine, 2002.
Establishment Size
1 to 9 employees
10 to 99 employees
100 or more employees
Total
Source: Allen and Gabe 2002.

Output

Employment

Establishments

$25,081,672
$92,415,825
$314,780,668
$432,278,165

165
749
2,775
3,689

52
23
5
80
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Table 2. Industry categories of Maine biotechnology firms.
Industry Category
Agricultural biotechnology
Genomics/proteomics
Human diagnostics
Human therapeutics
Environmental biotechnology
Industrial biotechnology
Marine biotechnology
Animal health

Biotech R & D

Biotech User

Industry Supplier

Total

-------------------------------------------- % ---------------------------------------26.4
18.1
19.6
26.9
8.7
13.8
14.3
21.6
17.7
17.4
33.0
38.0
15.2
0.0
6.0
15.6
23.9
16.7
24.3
35.8
11.9
3.2
9.3
21.2
23.9
9.2
18.1
31.3
25.6
22.8
17.7
30.2

95
Biotechnology Establishments
0 - 2 establishments
3 - 5 establishments
6 - 9 establishments
10 or more establishm ents

Figure 1. Locations of Maine biotechnology companies.Source: Allen and Gabe 2002.
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Cumberland and York counties (Allen and Gabe
2002). Many of the companies in southern Maine
owe their existence to two large biotechnology firms
in operation during the 1980s in the greater Portland area. When those firms were acquired by outof-state corporations and relocated out of Maine,
some former employees chose to remain in the state
and start their own companies (Colgan et al. 2002).
These spin-off companies, started by former
employees of established biotechnology firms, appear to be a major component of the biotechnology
cluster in southern Maine. According to the survey,
57% of the biotechnology businesses in Cumberland
and York counties were founded by individuals who
previously worked in other Maine biotechnology
firms. By comparison, approximately one-third of
the biotechnology businesses in the mid-Maine region (Androscoggin, Kennebec, Knox, Lincoln,
Sagadahoc, and Waldo counties) were founded by
former Maine biotechnology employees. None of the
companies located in other parts of the state was
started by former employees of Maine biotechnology companies.

BIOTECHNOLOGY INVESTMENT AND
INNOVATION
Table 3 documents the investments in facilities,
machinery and equipment, and research and development made by Maine biotechnology companies
during 2002. Forty percent of the businesses expanded their facilities, with nearly one-quarter of
them investing between $50,000 and one-half million dollars. By comparison, 88% of the biotechnology firms invested money in machinery and equipment, and 92% reported spending money on research and development. The high proportion of
businesses investing in research and development
is not surprising in light of the rapidly emerging
technological advances that characterize the bio-
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technology industry. For many companies, gaining
an economic advantage depends upon producing
new innovations, or at least keeping pace with
others in the industry by adopting current and
emergent technologies.
Table 4 shows the sources of funding that support the research and development expenditures
made by Maine’s biotechnology companies. The biotechnology firms in Maine rely heavily on ownsource funding for their investments in research
and development. During 2002, three-fourths of all
biotechnology firms reported using revenue generated through the sales of products and services to
fund some portion of their research and development activities. Across all biotechnology businesses,
own-source revenues provided an average of 63% of
total research and development expenditures. For
the biotechnology companies that used own-source
funding, it provided an average of 84% of their
budget spent on research and development.
The second most common source of research
and development funds is programs administered
by Maine-based agencies or organizations, such as
the Maine Technology Institute and the Finance
Authority of Maine. These agencies provided funding to 40% of Maine biotechnology companies in
2002 and accounted for an average of 9% of overall
spending on research and development. Other
sources of funds used for research and development
include venture capitalists, and programs sponsored by the U.S. government.
Table 5 shows the relative importance, by employment size category, of own-source funding compared to support received from the Maine Technology Institute. Larger businesses are considerably
more likely than smaller Maine biotechnology firms
to use in-house funds for research and development
investment. Only one-fourth of businesses with one
to four employees used own-source funds for research and development investments, while 87% of

Table 3. Investments in Maine biotechnology companies, 2002.
Amount of Investment

-------------------------------------------- Type of Investment ------------------------------------------------Expansion of facilities
Machinery and equipment
Research and development

Zero investment
Less than $50,000
$50,000 to $500,000
More than $500,000
Total

---------------------------------------------- % ------------------------------------------------------59.3
12.2
7.5
18.0
43.0
29.4
22.7
39.6
41.0
0.0
5.2
22.1
100
100
100
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Table 4. Sources of R&D funding, 2002.
Funding Source
Own-source revenues (sales)
Venture capital
State government programs
U.S. government programs
Other

Percentage of businesses
that use funding source

Mean percentage
of total spending

------------------------ % ----------------------75.0
63.3
12.9
10.2
40.0
9.2
14.0
5.1
15.5
1.6

Table 5. Key sources of R&D funding, by firm size.
Business size category
1 to 4 employees
5 to 9 employees
10 to 49 employees
50 or more employees

--------------- Source of funding for R & D spending -----------------Own-source revenues
Maine Technology Institute
----------------- Percentage of firms ----------------25.0
19.5
74.4
4.6
73.2
4.2
86.7
0.0

businesses with 50 or more employees reported
using own-source funds for that purpose.
On the other hand, small businesses are more
likely than larger firms to obtain funding from the
Maine Technology Institute. Nearly 20% of businesses with one to four employees obtained research and development funds from the Maine Technology Institute, compared to about 4% of the businesses with five to 49 employees. For those small
businesses that received Maine Technology Institute funding, it appears to be an important source of
revenue for research and development. The Maine
Technology Institute provided an average of 31% of
the research and development budget for businesses
with one to four employees, compared to 11% of the
research and development budget for businesses
with five to 49 employees.
The success of research and development activities in the biotechnology industry is often measured
by the number of patents and patents pending held
by businesses. The biotechnology businesses in
Maine hold an average of 2.3 patents and 0.7 patents pending. These patent numbers are highly
correlated with business size. Firms with fewer
than ten employees average 1.3 and 0.8 patents and
patents pending, respectively. The numbers increase
to 2.2 patents and 2.8 patents pending for business
with between 10 and 50 employees, and to 9.3
patents and 0.5 patents pending for businesses with
more than 50 employees.

Other indicators of innovative activity among
biotechnology companies include the articulation of
plans to increase the level of research and development, conduct new product trials, and release new
products. During the next three years, about onehalf of the businesses plan to increase their spending on research and development, 78% of the Maine
biotechnology firms plan to release a new product,
and 44% plan to enter into new product trials.

COOPERATIVE ACTIVITY
A key factor in the development of technologyintensive clusters (i.e., geographic concentrations of
economic activity established around a particular
industry or technology) is interaction among firms
and organizations. The sharing of knowledge, either directly through formal relationships or indirectly through the movement of workers between
companies, can be beneficial to all parties involved.
Table 6 summarizes the cooperative activities of
Maine biotechnology companies. The far right-handside column is the percentage of companies that
have been involved, at any time, in the selected type
of cooperative activity. Since some businesses have
been involved in multiple partnerships, the sum of
the percentages across each row may exceed the row
total in the far right-hand-side column. The bottom
row shows the percentage of Maine biotechnology
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Table 6. Partnerships of Maine biotechnology firms.
Cooperative activity
Conducted joint R&D
Submitted joint research proposal
Coordinated marketing effort
Shared equipment or personnel
Coordinated purchase of supplies
Shared technical information
Formed a strategic alliance
Shared facilities and space
Launched a new product
Total

Other Maine
Businesses

Non-Maine
Businesses

Maine Non-profit
Organization

Maine University
Researcher

Total

------------------------------------------------- % -------------------------------------------------22
39
11
20
58
14
18
14
10
31
6
20
0
0
21
18
2
8
14
32
6
9
5
0
19
27
35
18
21
56
8
21
2
6
28
18
13
9
16
41
6
28
0
0
26
50
61
32
36

companies that reported having ever engaged in
cooperative activity with the selected type of partner. Since businesses may have multiple interactions with the same types of partner, the sum of the
percentages down each column may exceed the
column total in the bottom row.
As shown in Table 6, Maine biotechnology firms
are more likely to have relationships with other
businesses than with Maine nonprofit organizations or university researchers located in Maine.
Fifty percent or more of the businesses reported
partnerships with other Maine companies and businesses located outside the state, while around onethird of the businesses have partnered with nonprofit organizations or university researchers located in Maine. The most common types of partnerships reported are joint research and development
efforts (58%) and the sharing of technical information (56%). Of all types of partnerships, businesses
are least likely to coordinate their purchases of
supplies (19%) or participate in a coordinated marketing effort (21%).
As shown in the far left-hand-side column of
Table 6, cooperation between Maine biotechnology
companies most frequently takes the form of shared
technical information (27%), joint research and development (22%) and shared facilities, space, equipment and/or personnel (18%). The most common
types of interaction with out-of-state companies are
joint research and development (39%), sharing technical information (35%), and launching a new product (28%). Our survey results show that Maine
businesses are more likely to engage in coordinated
marketing efforts and form strategic alliances with
out-of-state firms than with other businesses located in Maine. As might be expected, the biotechnology companies located in Maine are more likely
to share equipment and facilities with other Maine
firms than with companies located out of state.

The types of partnerships shown in Table 6 are
closely related to some of the most commonly used
business strategies of biotechnology companies.
These include the formation of joint ventures, participation in technology transfers, and the merger
with, or acquisition of, another business. To determine the direction that Maine biotechnology companies are headed in the near future, the survey
asked respondents to identify the business strategies that they planned to implement during the next
three years. As with the partnerships described in
Table 6, the business strategies shown in Figure 2
are more likely to be directed at businesses or
organizations located outside of the state than at
other Maine entities.
The most common strategy planned by a Maine
biotechnology firm over the next three years is the
creation of a joint venture with another business.
Twenty-two percent of businesses plan to enter into
a joint venture with another Maine business, while
35% plan to pursue a joint venture with a nonMaine business. The second most common planned
strategy involves obtaining a technology transfer
from a university. Twenty-five percent of businesses
plan to receive technologies from universities located outside of Maine, compared to 6% that plan to
obtain technology from a Maine university. Interestingly, a larger percentage of Maine firms are
planning a business acquisition than a merger with
another company. In either case, the acquisition or
merger target is more likely to be an out-of-state
company than another Maine business.
To further gauge the extent to which Maine’s
biotechnology companies are connected to the region, as well as to each other, we asked businesses
to indicate what they believed to be “important
sources” of biotechnology workers. As shown in
Table 7, close to 40% of the businesses viewed other
biotechnology businesses located within the state

8
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40%

35%

30%

with other Maine entities
with non-Maine entities

Percent

25%

20%

15%

10%

5%

0%

Joint venture

Technology transfer

Business acquisition

Business merger

Figure 2. Planned strategies of Maine biotechnology firms.
Table 7. Important sources of biotechnology
workers.
Source

Within
Maine

Outside
of Maine

Other biotechnology businesses
4-year universities
2-year colleges

---------- % --------39.4
25.7
33.1
30.1
8.8
2.9

as an important source of new employees. On the
other hand, a quarter of Maine biotechnology businesses felt that companies located out of state are a
key source of workers. One-third of the businesses
reported that Maine’s four-year universities are an
important source of employees, compared to 9% of
the companies that felt the state’s two-year colleges
are an important source of biotechnology workers.

ASSISTANCE RECEIVED BY MAINE
BIOTECHNOLOGY FIRMS
Economic development programs, offered at all
levels of government, are commonly used to encourage business growth and development. The U.S.
federal government administers programs that provide technical assistance in all aspects of business

operations, and financial support in the form of
grants, loans and tax relief. Thirty-four percent of
Maine biotechnology firms applied for federally
funded grants, and 32% successfully received such
funding. Fewer than 10% of businesses received
other types of assistance (e.g., government loans,
contracts, technical assistance) from the U.S. government.
In addition to business-assistance programs
sponsored by the U.S. government, the state of
Maine offers a variety of programs designed to
stimulate business growth (Table 8). Some of these
programs, such as the biotechnology sales tax exemption and programs that support research and
development, appear to be highly relevant to Maine
biotechnology firms. Although some businesses may
not qualify for certain state-sponsored programs, it
is noteworthy that, for six of the eight programs
included in the survey, a larger percentage of businesses are unaware of the program than the percentage that sought assistance. An exception to this
is the grant programs sponsored by the Maine
Technology Institute, which are well known and
well used by Maine biotechnology companies. More
than two-thirds of biotechnology companies either
have applied for, or received, grant funding from the
Maine Technology Institute, and only 8% are unaware of the programs.
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Table 8. State government programs for biotechnology.
State Government Programs

Sought or received assistance

------------------------ % ---------------------69
8
18
6
12
21
9
16
5
19
4
6
13
17
15
23

Maine Technology Institute grant
Employee training programs
Biotechnology sales tax exemption
Research expense credit
Super R&D credit
Tax increment-financing (TIF) incentive
Business Equipment Property Tax Reimbursement (BETR)
Research & development sales tax exemption

Less than 20% of Maine biotechnology businesses sought or received assistance from any of the
other programs included in the survey, and more
than 20% of the businesses are unaware of sales tax
exemptions available for research and development
or biotechnology-related expenditures. Only 13% of
businesses sought property tax reimbursements on
equipment and machinery through the BETR program, and 17% are unaware of the program’s existence. This is surprising given the significant publicity that has surrounded the program in recent years
and its availability to all businesses, regardless of
size or industry.
The respondents were also asked to indicate if,
beyond the provision of financial assistance, selected organizations in Maine played a role in the
establishment of partnerships, new product development, or establishment of new markets. Of these
three types of assistance, businesses were most
likely to receive assistance, from the sources listed
in Table 9, with new product development (41%),
followed by the establishment of partnerships (24%),
and new markets (15%).
As shown in Table 9, the organization that most
often provides these types of assistance to Maine
biotechnology companies is the Maine Technology
Institute (MTI). Thirty-nine percent of the businesses received assistance from the MTI in the area
of new product development, while 20% indicated
that the MTI was instrumental in the establish-

Unaware of the program

ment of a partnership. The Maine International
Trade Center provided assistance to Maine biotechnology businesses in the areas of establishing partnerships (12%) and establishing new markets (3%).
The University of Maine System assisted biotechnology businesses primarily in the areas of new
product development (8%) and the establishment of
partnerships (5%). No other organization provided
these types of assistance to more than 10% of the
businesses surveyed.

BUSINESS CLIMATE
A region’s business climate refers to the array of
attributes associated with a given location that
affect businesses, or that business people perceive
as having some impact upon their operations. These
locational characteristics typically include government policy as it relates to regulatory matters, but
can also take account of the availability of financing, education and workforce concerns, and lifestyle issues.
Maine biotechnology companies were asked to
respond to a number of business climate factors and
to indicate whether or not the factor is relevant to
the growth or profitability of the business. For each
relevant factor, respondents were asked to rate its
effect in Maine using a numerical scale ranging

Table 9. Entities that support Maine biotechnology firms.
Source of assistance
Maine Technology Institute
Maine International Trade Center
University of Maine System
Maine Dept. of Economic & Community Development
Maine Science and Technology Foundation
Maine Technical College System

Percentage receiving assistance
42.0
13.7
12.4
6.9
5.3
2.7
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Negative growth factors:
State sales and income taxes
Municipal property taxes
Workers Compensation costs
Healthcare costs
Utility costs
Neutral growth factors:
Access to in-state venture capital
Access to in-state debt financing
Availability of state funding for R&D
Distribution and transportation costs
Labor costs
State govt. business regulations
Local zoning and permitting regs.
State environmental regulations
Location relative to key markets
Location relative to suppliers
Availability of qualified employees
Access to university research info.
Availability of specialized equipment
Interaction with other biotech firms
Availability of business services
Quality of local schools
Local infrastructure and services
State and local tax incentives
Views of Maine policy makers
Support of local policy makers
Public perception of biotechnology
Strength of industry association
Positive growth factor:
Maine’s quality of life

Figure 3. Maine’s business climate for
biotechnology.
from “1” (very negative) to “7” (very positive). A
neutral effect is assigned a value of “4”.
Table 10 summarizes the survey results related
to the state’s business climate for biotechnology.
The table shows the percentage of businesses that
felt a particular factor affected its growth and the
average rating assigned by businesses that indicated the factor is a relevant issue.
For some of the factors shown in Table 10, the
average rating may be an imprecise indicator of the
factor’s impact on growth. This is because, in some
cases, the growth factor’s rating has a wide variation around its mean score. For example, a growth
factor that has an average rating that is slightly
greater (less) than 4.0, but that has a sufficiently
large variation around the mean, may not have a

statistically significant positive (negative) impact
on growth. We conducted statistical analyses of the
business-climate ratings to determine the factor
averages that are significantly greater, or less, than
a neutral rating of 4.0. The factors that have an
average rating that is significantly less than 4.0, at
a 10% significance level, are shown in Figure 3 as
“negative growth factors.” The factor that has an
average rating that is significantly greater than 4.0,
at a 10% significance level, is shown as a “positive
growth factor.”
As shown in Table 10, the business-climate
factors addressed in the survey generally are reported to be relevant to the biotechnology industry.
Only two business-climate factors, access to in-state
venture capital and access to in-state financing,
reportedly affect business growth for less than onehalf of Maine biotechnology companies. The business-climate factors that affect the largest percentages of companies are workers compensation costs,
health care costs, and utility costs. These were
reported to affect 92%, 92%, and 89% of biotechnology businesses, respectively. The biotechnology companies indicated that these business costs are negative growth factors.

Financing Issues
Less than 40% of the businesses reported that
access to in-state venture capital or debt financing
have an impact on the growth potential of their
business. Access to venture capital received an
average rating of 3.2, while the availability of instate debt financing received a rating of 4.7. Statesponsored programs, such as those offered by the
Maine Technology Institute, affect 64% of biotechnology businesses. These programs received a mean
rating of 4.8. None of the financing issues included
in the survey received an average score that is
significantly different from a neutral rating of 4.0.

Business Costs and Regulations
The survey asked businesses to rate ten business climate factors that reflect the costs of doing
business in the region. Some of these factors, such
as workers compensation and health care costs, are
considered to be relevant issues by more than 90%
of biotechnology businesses. Other business costs
and regulations, such as distribution and transportation costs, local zoning and permitting, and state
environmental regulations, affect fewer than 65%
of biotechnology businesses. The cost of labor is the
only factor in this category to receive a rating
greater than 4.0, but the average score of 4.1 is not
significantly greater than a neutral rating of 4.0.
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Table 10. Average ratings of business-climate factors.
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Health care costs, a factor with the most widespread impact, received the lowest score (mean
score of 1.5) of all business-climate factors. Other
factors in this section that received among the
lowest business-climate ratings are state sales and
income taxes (mean score of 2.1), workers compensation costs (mean score of 2.2), municipal property
taxes (mean score of 2.3), and utility costs (mean
score of 2.6). Each of these factors received an
average score that is significantly less than a neutral rating of 4.0. This implies that these business
cost factors are perceived to have a negative effect
on the growth of Maine biotechnology businesses.

Local Issues
This category includes business-climate factors
that may pertain to the town or city where the
business is located. These factors capture general
characteristics of the local area, such as the quality
of local schools and infrastructure, as well as the
benefits that businesses are believed to receive from
operating within an industry cluster. These benefits, which are external to the business but internal
to the cluster, may include the presence of a skilled
workforce, the availability of specialized machinery, and the ability to interact with other biotechnology businesses. None of the factors in this category received an average score that is significantly
different from a neutral rating of 4.0.
Three of the location factors in this category are
relevant to a relatively large percentage of the
biotechnology companies. The availability of qualified biotechnology employees and access to university based research information affect 81% and 82%
of the businesses, respectively. Seventy-eight percent indicated that business growth is affected by
their ability to interact with other biotechnology
companies.

Other Business-Climate Factors
This category includes six additional businessclimate factors. Three of these reflect the level of
support for biotechnology from outside of the industry, as perceived by companies within the industry.
The views of Maine state government policymakers,
support of local policymakers, and the public’s perception of the biotechnology industry all appear to
be relevant issues to Maine’s biotechnology businesses. As might be expected, the views of state
government policymakers are reported to affect a
substantial percentage of biotechnology businesses
(84%), followed by the views of local policymakers
(77%), and the public’s perception of the industry
(66%). None of these business climate factors re-

ceived an average score that is significantly different from a neutral rating of 4.0.
Sixty-one percent of the companies indicated
that the strength of the biotechnology industry
association affects the growth of their business. The
industry association(s) received an average score of
3.7, which is not significantly different from a neutral rating of 4.0. Finally, the quality of life offered
by a Maine location is perceived to affect the growth
of 85% of the biotechnology businesses. With an
average rating of 5.8, Maine’s quality of life is the
highest ranked growth factor and the only factor
covered in the survey that received an average score
that is significantly greater than a neutral rating of
4.0. The state’s quality of life appears to be a positive
force in the industry’s business climate.

RESPONSES TO OPEN-ENDED
QUESTIONS
The survey included several open-ended questions that asked biotechnology companies to comment on the strengths and weaknesses of operating
in Maine and the changes they believe would help
their competitiveness. The responses to these questions generally reinforced the trends revealed elsewhere in the survey. When asked to indicate what
actions, policy changes, or assistance the state of
Maine could provide to enhance the competitiveness of biotechnology firms, the most frequent response (43% of firms) involved lowering the costs of
doing business. This notion is further supported by
the responses provided to another open-ended question that asked the firms to indicate the three
primary drawbacks of operating a biotechnology
business in Maine. Of the 38 firms that provided a
response, two-thirds remarked on the high costs of
doing business in Maine. Although high taxes were
the most frequent target, other cited costs included
the expense of providing health care coverage for
employees and the cost of workers compensation.
The second most frequent suggestion (25% of
respondents) for improving the competitiveness of
biotechnology businesses centered on the issue of
financing. Some firms pointed to the need to attract
more federal research and development dollars,
while others felt that some state government funding programs were not accessible to all businesses.
Nearly as many respondents (21% of the businesses)
indicated that improved access to technical resources
could help improve the industry’s competitiveness.
This is reinforced by the relatively large group (29%
of respondents) that reported a lack of research and
development resources in the state as one of the
primary drawbacks to doing business in Maine.
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Specifically, 20% of the respondents mentioned several issues of concern related to the University of
Maine system, including the location, amount, and
accessibility of university resources.
The second most often-cited drawback to operating a biotechnology business in Maine, behind the
costs of doing business, is the state’s remote location
relative to national centers of biotechnology activity. This concern, cited by 60% of the respondents,
generally revolved around a firm’s perceived isolation from developments in the industry and the
difficulty of recruiting scientists from outside of
Maine. Despite these feelings of isolation, about
60% of the businesses believed they would not benefit from greater interaction with other biotechnology businesses. The most common explanation for
this response is that Maine biotechnology businesses are too specialized to benefit from (general)
collaborations that are not specific to their company’s
activities.
In response to the question of why their business is located in Maine and why they stay here, the
largest numbers of respondents mentioned Maine’s
quality of life (55%), or indicated that the firm’s
founder was already living in Maine when the company was established (55%). Other firms (26%),
especially those involved in aquaculture, referred to
the presence of the state’s natural resources as a
primary reason for locating in Maine. Finally, some
businesses (17%) indicated that the state’s labor
force is a primary benefit of operating in Maine.
Most comments in this regard, however, referred to
the strong work ethic and dependability of Maine
workers, while no one positively remarked about
the educational background of the state’s workforce.
On the contrary, almost 20% of the respondents
cited the limited availability of qualified employees
as a drawback to operating in Maine.

SUMMARY AND CONCLUSIONS
The Maine biotechnology industry is made up of
about 80 businesses. These companies are engaged
in research and development in addition to the
manufacturing and provision of a wide variety of
products and services. Although the industry is
defined based upon the use and support of a common general technology, businesses that constitute
the industry appear to be quite diverse in terms of
the specific focus area of biotechnology. The businesses cover a broad spectrum of the biotechnology
industry, from human diagnostics to marine biotechnology to genomics and proteomics. This diversity likely explains some of the survey findings
related to the limited benefits from industry clus-

13

tering. Further, the lack of a critical mass in any one
type of biotechnology likely explains why some Maine
biotechnology companies are just as likely, or even
more likely, to partner with companies and universities located outside of Maine than to cooperate
with other in-state entities.
The survey results suggest that Maine biotechnology companies are actively involved in research
and development, which is key to success in technology-intensive industries. Large companies generally finance the bulk of their research and development expenditures through their own revenue
sources, while small businesses are likely to receive
support for research and development from statesponsored programs such as those administered by
the Maine Technology Institute. The research and
development activities in Maine biotechnology companies appear to be leading to new products, as 78%
of the businesses are planning to release a new
product in the next three years. Further, Maine
biotechnology companies hold an average of 2.3
patents and 0.7 patents pending.
The evidence is mixed on the question of whether
the biotechnology industry in Maine generates substantial cluster benefits. On the one hand, the industry is highly concentrated in southern Maine
and a large number of biotechnology businesses in
that area are the result of spin-off ventures started
by former employees of other biotechnology businesses. On the other hand, industry cluster benefits
related to the presence of a skilled workforce, the
availability of specialized machinery, and intrabusiness knowledge spillovers appear to be limited
in Maine. Further, Maine biotechnology businesses
are more likely to seek cooperative links with firms
and universities located outside of the state than
with other Maine-based entities. Firms appear to be
collaborating with entities from outside of the state
because suitable partners are not located within the
state. This is, again, likely a result of the high
diversity within the Maine biotechnology industry.
Biotechnology companies generally believe that
many of the costs of doing business in the state are
harmful to their growth. The majority of survey
respondents feel that the costs of health care, workers compensation, utilities, and state and local taxes
are relevant to the growth of their business. Further, statistical analysis of the survey results suggests that these cost factors are perceived to have a
significant negative effect on a biotechnology
company’s ability to grow in Maine. On the other
hand, the businesses indicated that the quality of
life in Maine has a significant positive effect on their
ability to grow. The rest of the business climate
factors included in the survey do not appear to have
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a significant effect, one way or the other, on the
growth of Maine biotechnology businesses.
Based on the survey results and analysis presented in this report, we offer the following recommendations to support the biotechnology industry
in Maine. First, the state should recognize the
industry’s diversity when designing biotechnologyrelated programs and services. Programs targeted
at specific types of biotechnology will affect only a
small number of firms, while a larger percentage of
the overall industry could potentially benefit from
general services and programs. Moreover, there is
no clear evidence that a cluster has yet emerged
around a specific type of biotechnology that could be
the target for specialized assistance. At this stage of
the industry’s development, it is important that
programs make their assistance available to firms
across the industry regardless of specific technology
or firm size. Concentrating on a more general approach would benefit all types of biotechnology
firms, as well as businesses in other technologyintensive industries.
Second, the state should widely promote the
economic development programs available to biotechnology companies. As discussed earlier in the
report, a relatively small percentage of businesses
have used programs other than those offered by the
Maine Technology Institute. In many cases, the
percentage of businesses that have used a program
is actually smaller than the percentage that is
unaware of the program’s existence. Similarly, businesses in the industry reported only limited interaction with university researchers located within the
state. The level of industry diversity and variety of
research projects at Maine colleges and universities
suggests that improved coordination and communication could increase the potential for industryuniversity partnerships. The programs available to
biotechnology companies could be promoted through
the administering agencies, the state’s industry
association, and the newly formed biotechnology
interactive network.
Third, the state should continue to support
investments in basic research and development.
Nearly two-thirds of the survey respondents believe
that the availability of state government funding
for research and development is relevant to the
growth of their business. Further, the state-sponsored research and development programs appear
to be especially important to small biotechnology
companies, which are less likely than larger firms to
finance research and development through revenues generated by the business. Once again, programs that support basic research in all types of
biotechnology would benefit a larger number of

firms than programs targeted at specific types of
research and development.
Fourth, further analysis should be conducted on
the costs of doing business in Maine, including the
costs of health care, workers compensation, utilities, and taxes. The biotechnology companies were
in almost unanimous agreement that these costs
are relevant to their operations, and the businesses
generally felt that these location factors in Maine
have a negative effect on their ability to grow.
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APPENDIX: SURVEY INSTRUMENT

The Business Climate for Biotechnology in Maine

Survey conducted by:
Department of Resource Economics and Policy
University of Maine

In cooperation with:
The Biotechnology Association of Maine
and
The Maine Center for Innovation in Biotechnology
February 2003
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Survey Information and Instructions
Please complete and return this voluntary survey if your establishment performs biotechnology research
and development, manufactures biotechnology-related products, uses biotechnology in manufacturing
or provision of services, or provides goods and services that are used by biotechnology companies.
Our goal is to treat your responses with the utmost confidentiality. Do not write your name or the name
of your establishment on the survey. Your establishment name is written on the postcard. The returned
postcards will provide us with an accurate account of which companies participated in the study.
Your responses to the survey are strictly confidential and will never be associated with your name or the
name of your business. Study results will be presented only in aggregate for the entire industry or for
subsets of the industry that contain three or more businesses. Individual surveys will be processed by
a single researcher at the University of Maine. The completed surveys will be stored in a locked file
cabinet and will be shredded upon completion of the study.
Please make sure that all of your responses are complete. You may, however, skip over any
question that you feel uncomfortable answering. Also, you may write additional comments in the
margin of the survey.
If information required to answer a question is not readily available, please provide the most accurate
estimate possible. If an item does not apply to your firm, please designate with the letters “N/A.”
The survey should take approximately 20 minutes to complete. Except for your time and inconvenience,
there are no risks to participating in the study.
Questions related to this survey should be directed to:
Todd Gabe, Assistant Professor, (207) 581-3307
Thomas Allen, Associate Scientist, (207) 581-3164
Questions related to your rights as a study participant should be directed to:
Gayle Anderson, Special Assistant for Research Administration, (207) 581-1498
Please return the completed survey, in the enclosed pre-addressed envelope, to the address shown below.
Returning the survey implies consent to participate.
Biotechnology Survey
Department of Resource Economics and Policy
University of Maine
5782 Winslow Hall
Orono, ME 04469-5782
Thank you for your participation.
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The Business Climate for Biotechnology in Maine
1) In what year was your organization or business established in Maine? ________________

2) How many years has your establishment been operating at its current location? _________
3) From the following list, please check the option(s) that best describe(s) the ownership
structure of your establishment:
____ proprietorship or partnership (any form)
____ privately-owned corporation
____ publicly-owned corporation
____ non-profit organization
____ other (please indicate: ________________________________________________ )

4) From the following list, please check the option(s) that best describe(s) the organizational
structure of your establishment:
____ single establishment firm
____ headquarters of multi-establishment firm
____ branch plant of multi-establishment firm
____ establishment of a multi-national corporation
____ other (please indicate: ________________________________________________ )

5) From the following list, please check the option(s) that best describe(s) the primary activity
of your establishment:
____ research and development
____ making a product(s)
____ providing a service
____ other (please indicate: ________________________________________________ )

6) Where is your establishment located?
___________________ Zip Code

___________________ County

7) Was the founder of this business previously employed by another biotechnology-related
business in Maine?
Yes

No
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8) For each category of biotechnology that applies to your establishment, please indicate if your
establishment a) conducts research and development in biotechnology, b) uses
biotechnology or biotechnology products in manufacturing or provision of services, or c)
supplies other products or services used by biotechnology companies (check all that apply).
Category

Biotech
R&D

Uses
Biotech

Industry
Supplier

Agricultural biotechnology (e.g., biopesticides, diagnostics, genetically
modified foods, natural fertilizers, nutraceuticals)
Genomics / proteomics (e.g., bioinformatics, DNA diagnostics,
pharmacogenetics)
Human diagnostics (e.g., biological sensors, gene tagging, monoclonal
antibodies, polymerase chain reaction amplification)
Human therapeutics (e.g., biopharmaceuticals, gene therapy, human
growth hormones, vaccines)
Environmental biotechnology (e.g., biofiltration, bioremediation,
environmental monitoring, immunoassays, microbial mining,
phytoremediation)
Industrial biotechnology (e.g., specialty amino acids and enzymes,
bioprocessing, phytochemicals, other industrial activities)
Marine biotechnology (e.g., aquaculture, new classes of human health
and medical products, and other chemical products)
Animal health (e.g., animal diagnostics and therapeutics, monoclonal
antibodies, transgenic animals)
Other (please indicate:___________________________________________________________________
_____________________________________________________________________________________

9) How many workers in total did your establishment employ as of January 1, 2003?
__________ Full-time employees
__________ Part-time employees

10) How many of these workers have biotechnology-related responsibilities?
__________ Full-time employees
__________ Part-time employees

11) Does your firm currently have any full-time biotechnology-related positions that have been
unfilled for more than three months?
Yes
No
If yes, please describe the position(s): ______________________________________________________
__________________________________________________________________________________________
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12) What is the approximate number of full-time workers with biotechnology-related
responsibilities in each of the following occupations?

Occupation

Number of
Employees

Scientists
Engineers
Laboratory Technicians
Computer Programmers and Information Technology
Managers and Supervisors

13) What is the approximate number of full-time workers with biotechnology-related
responsibilities that have obtained the following (highest) levels of education?
Level of Education

Number of
Employees

High school diploma or general education degree
Graduate of 2-year community college, or technical school
Graduate of 4-year university (B.S. or B.A. degree)
Master’s degree
Doctorate degree

14) Indicate which of the following have been important sources of biotechnology workers for
your establishment (check all that apply).
Background
Another establishment located in Maine
Another establishment located elsewhere in the U.S.
4-year university located in Maine
4-year university located elsewhere in the U.S.
2-year university located in Maine
2-year university located elsewhere in the U.S.
Establishment or university located outside the U.S.
Other (please specify):______________________________

Important Source of
Biotechnology Workers
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15) What was your establishment’s total sales revenue in 2002?
Zero

Zero to $250K

$250K to $500K

$500K to $750K

$750K to $1 million

$1 million to $2.5 million

$2.5 million to $5 million

$5 million to $10 million

More than $10 million

16) How much did your establishment receive in total grants in 2002?
Zero

Zero to $250K

$250K to $500K

$500K to $750K

$750K to $1 million

$1 million to $2.5 million

$2.5 million to $5 million

$5 million to $10 million

More than $10 million

17) How much did your establishment receive in total contracts or fees in 2002?
Zero

Zero to $250K

$250K to $500K

$500K to $750K

$750K to $1 million

$1 million to $2.5 million

$2.5 million to $5 million

$5 million to $10 million

More than $10 million

18) How much did your establishment spend on facility expansions in 2002?
Zero

Zero to $250K

$250K to $500K

$500K to $750K

$750K to $1 million

$1 million to $2.5 million

$2.5 million to $5 million

$5 million to $10 million

More than $10 million

19) How much did your establishment spend on new equipment and machinery in 2002?
Zero

Zero to $250K

$250K to $500K

$500K to $750K

$750K to $1 million

$1 million to $2.5 million

$2.5 million to $5 million

$5 million to $10 million

More than $10 million

20) How much did your establishment spend on payroll (including benefits) in 2002?
Zero

Zero to $250K

$250K to $500K

$500K to $750K

$750K to $1 million

$1 million to $2.5 million

$2.5 million to $5 million

$5 million to $10 million

More than $10 million

21) How much did your establishment spend on research and development in 2002?
Zero

Zero to $250K

$250K to $500K

$500K to $750K

$750K to $1 million

$1 million to $2.5 million

$2.5 million to $5 million

$5 million to $10 million

More than $10 million

Maine Agricultural and Forest Experiment Station Miscellaneous Report 432

21

22) What percentage of your establishment’s research and development budget in 2002 came
from the following sources?
Percentage of
R&D Budget

Revenue Source
Revenue generated by product sales

%

Conventional loans

%

In-state venture capital

%

Out-of-state venture capital

%

Grants or loans from the U.S. government

%

Grants or loans from the Finance Authority of Maine (FAME)

%

Grants or loans from the Maine Technology Institute (MTI)

%

Grants of loans from another Maine agency/program: _____________

%

Grants from a private research foundation

%

Other (please indicate:___________________________)

%

Total

100 %

23) How many patents or patents pending does your establishment have?
________ patents

________ patents pending

24) What percentage of your establishment’s total sales in 2002 was generated from foreign
exports of biotechnology products or processes?
Zero

Zero to 10 percent

10 percent to 25 percent

25 percent to 50 percent

50 percent to 75 percent

75 percent to 100 percent

25) Please list the four countries that received the highest percentage of your establishment’s
exports in 2002.
1._________________________________________________________
2._________________________________________________________
3._________________________________________________________
4._________________________________________________________
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26) What percentage of your purchased inputs, materials or equipment is obtained through
foreign imports?
Zero

Zero to 10 percent

10 percent to 25 percent

25 percent to 50 percent

50 percent to 75 percent

75 percent to 100 percent

27) Please list the four countries from which your establishment purchased the highest
percentage of imported goods in 2002.
1._________________________________________________________
2._________________________________________________________
3._________________________________________________________
4._________________________________________________________

28) Please check the following business strategies that your business has used in the last 12
months, or is planning to use in the next 12 months, or next 3 years (check all that apply).
Strategy
Release a new product
Enter product trials
Substantial increase in research and development activities
Form a joint venture with another Maine establishment
Form a joint venture with establishment outside of Maine
Technology transfer from a university located in Maine
Technology transfer from a university located out of Maine
Acquire another establishment located in Maine
Acquire another establishment located outside of Maine
Merge with another establishment located in Maine
Merge with another establishment located outside of Maine
Relocate outside of Maine

Last 12
months

Next 12
months

Next 3
years
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29) Check the expansion activities that your establishment has completed in the last 12 months,
or is planning to complete in the next 12 months, or next 3 years (check all that apply).
Last 12
months

Expansion Activity

Next 12
months

Next 3
years

Expand facilities by less than 2,500 square feet
Expand facilities by 2,500 to 10,000 square feet
Expand facilities by more than 10,000 square feet
New equipment purchases of less than $1 million
New equipment purchases of $1 million to $10 million
New equipment purchases of more than $10 million

30) Please indicate whether your establishment has been involved in any of the following types
of interaction with the federal government during the past three years (check all that apply).
U.S. Government Interaction

Past 3 years

Received technical assistance from the U.S. government
Applied for grants from the U.S. government
Received government grants from the U.S. government
Obtained federal government loans
Awarded a federal government contract
Other (please indicate):______________________________

31) Please indicate if, during the past three years, your establishment sought or received
assistance from the following Maine state government programs (check all the apply).
State Government Programs
Maine Technology Institute (MTI) grant
Employee training programs
Biotechnology sales tax exemption
Research expense credit
Super R&D credit
Tax increment-financing (TIF) incentive
Bus. Equip. Property Tax Reimbursement (BETR)
Research & development sales tax exemption
Other (please indicate): ____________________

Sought
Assistance

Received
Assistance

Unaware of
the Program
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32) Please indicate if your business has ever engaged in the following types of cooperation with other
biotechnology businesses in Maine, other biotechnology businesses located outside of Maine, nonprofit organizations in Maine, or University of Maine researchers (check all that apply).

Cooperative activity

Other Maine
Businesses

Non-Maine
Businesses

Maine
Non-profit
organization

Maine
University
Researcher

Conducted joint R&D
Submitted a joint research proposal
Coordinated marketing effort
Shared equipment or personnel
Coordinated purchase of supplies
Shared technical information
Formed a strategic alliance
Shared facilities and space
Launched a new product

33) Please indicate whether each of the following Maine state-sponsored agencies, programs or
institutions have ever contributed to the establishment of partnerships, new product
development, or new markets for your business (check all that apply).
Cooperative activity
University of Maine System
Maine Technical College System
Maine Science & Technology Foundation
Maine Technology Institute
Dept. of Economic & Community Development
Maine International Trade Center
Other: _________________________

Establishment of
Partnerships

New Product
Development

Establishment of
New Markets
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34) Please rate the degree to which the following factors in Maine affect your establishment’s
profitability or growth potential, with 1 being a strongly negative factor and 7 being a
strongly positive factor. If it does not affect your business’s growth, select “Not a factor”.
Not a
Factor

FINANCING
Access to in-state venture capital
Access to in-state debt financing
Availability of state government funding for R&D

BUSINESS COSTS AND REGULATIONS
Distribution and transportation costs
Labor Costs
State sales and income taxes
Municipal personal property tax
Worker’s Compensation costs
Health care costs
Utility costs
State government business regulations
Local zoning and permitting practices
State environmental regulations

LOCATION ISSUES
Location relative to key output markets
Location relative to key materials & supplies
Availability of qualified biotechnology employees
Access to university-based research information
Availability of specialized equipment
Interaction with other biotechnology businesses
Availability of business services (legal, accounting, etc.)
Quality of local schools (K-12)
Local infrastructure and public services

OTHER
State and local tax incentives
Views of Maine government policymakers
Support of local (i.e., municipal/regional) policymakers
Public perception of biotechnology industry
Strength of state industry association(s)
Maine’s quality of life

Negative
1
2

3

4

5

Positive
6
7
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35) If your establishment has not collaborated with other businesses or organizations in the past,
do you feel that it could benefit from greater interaction with other biotechnology firms in
the future?
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________

36) What additional actions, policy changes, regulatory reforms, or assistance could the State
of Maine take or provide to help your establishment improve its competitiveness?
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________

37) What are the three primary factors that led you to locate and/or maintain your business in
Maine?
1) _______________________________________________________________________
2) _______________________________________________________________________
3) _______________________________________________________________________

38) What are the three primary drawbacks of operating your business in Maine?
1) _______________________________________________________________________
2) _______________________________________________________________________
3) _______________________________________________________________________
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